Mediators of Inflammation

Mediators of Inflammation / 2019 / Article

Research Article | Open Access

Volume 2019 |Article ID 2153934 | 7 pages | https://doi.org/10.1155/2019/2153934

Adiponectin Expression Is Modulated by Long-Term Physical Activity in Adult Patients Affected by Cystic Fibrosis

Academic Editor: Michele T. Pritchard
Received04 Jan 2019
Accepted04 Aug 2019
Published09 Sep 2019

Abstract

Cystic fibrosis (CF) is a genetic disease characterized by progressive decline of lung function and chronic airway inflammation. Adipose tissue, through adiponectin and leptin, exerts several effects on energy metabolism and inflammatory processes. This study evaluated the levels of adiponectin and leptin in adult healthy subjects, in patients with CF and their correlation with long-term physical activity. CF patients were divided into two groups (sedentary versus active) based on their regular physical activity over 3 years. Anthropometric and serum biochemical profiles of CF patients and controls were evaluated and compared. Total serum adiponectin and leptin levels were measured by ELISA; adiponectin oligomeric profiles were analysed by western blot. Adiponectin levels were significantly higher while leptin levels were lower in patients with CF than in healthy controls. Furthermore, adiponectin was significantly lower in active compared to sedentary CF (), while leptin was slightly increased in active compared to sedentary CF. In addition, C-reactive protein levels were significantly lower in active than in sedentary CF patients (). Interestingly, only in the active group adiponectin levels were inversely correlated with forced expiratory volume (FEV) 1% decrease/year and FEV1% decrease. Moreover, adiponectin levels negatively correlated with lipid profiles. Our findings indicated that regular, long-term physical activity in CF improves respiratory function, metabolism, and inflammation status. These improvements in patients’ conditions are associated with immunometabolic processes involving adiponectin, leptin, and C-reactive protein. Therefore, we propose that both adipokines may be a useful biomarker in the evaluation of metabolic and inflammatory status in patients with CF.

1. Introduction

Cystic fibrosis (CF) is the most common autosomal recessive disorder in Caucasian populations. Patients with CF show a severe decline of pulmonary function related to chronic airway inflammation [1]. Recent studies suggest that inflammation occurs very early in pathogenesis and may even occur in the absence of infection; a deregulation of cytokine production and abnormal epithelial host defenses probably underlie and sustain inflammation [2]. A marked and persistent inflammatory process occurs very early in the course of CF and is present in mild as well as in stable disease [3]. Beyond the pulmonary phenotype, patients with CF frequently display alterations in peripheral muscle endurance, likely primarily due to physical inactivity.

The positive effects of physical exercise on body composition, insulin sensitivity, and blood glucose levels have been demonstrated in multiple morbid conditions, including different lung diseases [4, 5]. Respiratory muscle training, physiotherapy, and moderate physical activity have been shown to improve respiratory function in patients with CF [46]. Thus, it would be useful to identify biochemical mechanisms involved in such improvement.

Adiponectin is an abundant serum adipokine composing up to 0.05% of total circulating protein [7]. After its secretion by adipocytes, adiponectin oligomerizes in three forms: trimers of low molecular weight (LMW), hexamers of medium molecular weight (MMW), and multimers of high molecular weight (HMW) [8]. HMW multimers are the most active oligomers in their biological properties [8]. In non-obesity-related inflammatory disorders, adiponectin levels are increased [911].

Adiponectin plays a role in lung diseases and obesity; indeed, its receptors are expressed in lung epithelium; its serum levels are increased in patients with Chronic Obstructive Pulmonary Disease (COPD) [11]. In addition, data from in vitro studies on lung cells were consistent with an anti-inflammatory function of adiponectin [11, 12], and adiponectin-deficient mouse models develop lung function impairment and systemic inflammation [13, 14]. In the development and progression of lung cancer, a pathogenic role of adiponectin was defined by both in vivo and in vitro studies [15, 16].

Leptin is involved in various inflammatory diseases. In the lung, leptin exerts proinflammatory effects [17]. In the presence of lung inflammatory stimuli, increased leptin concentrations have been associated with symptom intensification and exacerbation [17].

Many studies suggest that exercise is associated with adiponectin and leptin levels in different metabolic diseases [17, 18], but to our knowledge, there are no studies on the effects of exercise on these two adipokines in patients with CF. In this study, we investigated the effects of 3 years of physical training on adiponectin and leptin serum concentrations in a cohort of CF patients compared to a control group of sedentary patients. We also measured correlations between serum adiponectin and leptin levels and biochemical and clinical parameters in the two patient groups. The results were further compared to those from a group of healthy subjects.

2. Materials and Methods

2.1. Patients

The study population consisted of 116 CF patients who received diagnosis at the regional CF care center of Campania (Southern Italy). All patients who met the diagnostic criteria for CF [19] were over 18 years of age and had pathological SCL () and two class I-II CFTR mutations. Among the 116 patients, 58 regularly performed physical exercise in the last three years (exercise group) and 58 age-matched patients did not perform physical exercise in the last three years. Patients belonging to the exercise group performed physical exercises individually selected by and under the supervision of a team composed of a physician trained in CF, a nutritionist, and a physiotherapist. This team was responsible for monitoring each patient with particular attention to his/her hydration and type of physical activity, to prevent salt depletion syndrome or other complications. Furthermore, the team monitored the compliance of the patients with exercise training. Informed consent was obtained from all participants. Ninety-eight healthy volunteers aged years constituted the control group (). The research protocol was conducted in accordance with the principles of the Helsinki II Declaration. According to the current legislation in Italy, we obtained informed consent from each subject for anonymous use of clinical data for research purposes.

2.2. Clinical Evaluation

Sweat chloride levels were tested as previously described [20] and a panel of CFTR mutations was screened [21]. The best FEV1, expressed as percentage of predicted value for age, according to standardized reference equations for spirometry [19] were recorded. Airway colonization by Pseudomonas aeruginosa, pancreatic sufficiency (PS), and liver disease (CFLD) was assessed as previously described [6, 22]. Diagnosis of CFRD was made according to the American Diabetes Association criteria [23].

2.3. Anthropometric Measurements

We recorded the height, weight, BMI, waist circumference, and upper arm circumference of CF patients and healthy controls as previously described [6]. Body weight was measured in a fasting state in the morning with a mechanical balance (±0.1 kg, SECA 700, Hamburg DE). BMI was calculated as body weight divided by height squared (kg/m2) with categories in accordance with the World Health Organization guidelines [24]. To define subjects with alterations in BMI and circumferences, we used reference intervals normalized to the age of each patient [24].

2.4. Biochemical Parameters

Blood samples () were collected from the participants after an overnight fast, and serum samples were separated. Serum albumin, insulin, C-reactive protein, glucose, total cholesterol, HDL and LDL cholesterol, and triglycerides were measured as previously described [6]; all assays were performed with an automated biochemistry analyser (Architect ci16200 Integrated System, Abbott Diagnostics, Rome, Italy). The HOMA index was calculated as [23]. Concentrations of total adiponectin in serum were measured in triplicate by an enzyme-linked immunosorbent assay (ELISA) as previously described [25]. A Sandwich-ELISA assay was used to measure leptin concentration in serum samples (Elabscience, Houston, Texas, USA).

2.5. Western Blotting Analysis

Serum samples from all participants were quantified for total proteins by Bradford assay (Bio-Rad, Hercules, CA, USA), and 10 μg of total protein was heated in 1X Laemmli buffer at 95°C for 10 min and loaded on 10% SDS-PAGE gels as previously described [11]. The immunoblots were developed by ECL (Amersham Biosciences, Piscataway, NJ, USA) with the use of Kodak BioMax Light film, digitalised with a scanner (1200 dpi), and analysed by densitometry with ImageJ software (https://imagej.nih.gov/ij/). Each sample was tested three times in duplicate.

2.6. Statistical Analysis

All data are expressed as . The Kolmogorov-Smirnov test was used to test the normality of distributions. Student’s -test or the Mann-Whitney test for independent samples were used to compare parametric and nonparametric numerical data, respectively. Frequencies of categorical variables were compared by Chi-square tests. Adiponectin serum concentrations were correlated by Pearson’s or Spearman’s rho tests, according to data distribution. A value < 0.05 was considered statistically significant. Multiple comparisons on western blotting experiments were performed by ANOVA tests. All statistical analyses were performed with the Statistical Package for Social Sciences software for Windows (SPSS Inc.).

3. Results

3.1. Anthropometric and Biochemical Features of Patients with CF

Anthropometric and serum biochemical profiles of CF patients and control healthy subjects are reported in Table 1.


CN subjects ()CF patients () value

Age (years)31.1 (7.6)30.9 (8.7)n.s.
Sex male/female55/4359/57n.s.
Body mass index (kg/m2)23.4 (3.0)22.4 (3.6).001
Total chol (mg/dL)190.2 (35.3)140.9 (36.6).000
Triglycerides (mg/dL)86.5 (53.7)79.6 (29.5)n.s.
HDL chol (mg/dL)56.6 (15.2)47.0 (14.3).000
LDL chol (mg/dL)114.8 (30.2)78.0 (28.0).000
Non-HDL chol (mg/dL)133.6 (35.9)93.9 (31.2).000
Tot/HDL chol ratio (%)3.6 (1.2)3.1 (0.8).010
Non-HDL/HDL chol ratio (%)2.6 (1.2)2.1 (0.8).010
Serum fasting glucose (mg/dL)83.2 (12.8)90.8 (17.6).000
Albumin (g/dL)4.7 (0.4)4.3 (0.4).000
Adiponectin (μg/mL)10.2 (1.6)13.2 (2.2).000
Leptin (ng/mL)12.0 (6.1)9.2 (11.2).003

values by -test, Mann-Whitney test or Chi-square test; n.s.: not significant.

All subjects were matched for age and sex. Data are shown in Table 1. BMI values were significantly lower in patients with CF compared to controls. CF patients had significantly lower cholesterol lipid and significantly higher glucose levels than controls. Adiponectin serum levels were increased in CF patients vs. controls, while leptin levels are significantly decreased in CF patients vs. controls.

After the comparison to healthy subjects, we divided the CF patients into two age- and sex-matched subgroups and compared anthropometrical, biochemical, and disease-specific parameters between patients that regularly performed physical exercise in the last three years and sedentary patients. Table 2 shows that these two subgroups (active and sedentary) significantly differed for both FEV1% decrease/year and FEV1% decrease. In the active group, triglyceride levels were significantly lower than in the sedentary group. Serum adiponectin levels were significantly lower in active versus sedentary CF patients, respectively. On the contrary, leptin levels are slightly decreased in sedentary CF patients vs. active patients, although the difference is not significant. Finally, C-reactive protein levels were significantly lower in the active group than in the sedentary group.


CF physical activity group ()CF sedentary group () value

Age (years)30.7 (8.3)31.1 (9.2)n.s.
Sex (male/female)29/2930/28n.s.
Body mass index (kg/m2)22.4 (3.2)22.4 (4.0)n.s.
Waist circumference (cm)80.0 (8.9)81.5 (9.7)n.s.
Hip circumference (cm)93.4 (7.6)92.8 (9.1)n.s.
Waist/hip ratio (%)86.2 (8.9)88.1 (8.4)n.s.
FEV1% decrease/year0.46 (3.58)1.13 (5.01).044
FEV1% decrease (%)0.87 (4.77)1.03 (8.02).008
Total cholesterol140.3 (37.3)141.6 (36.2)n.s.
Triglycerides (mg/dL)72.7 (20.6)86.6 (35.2).012
Serum fasting glucose (mg/dL)90.0 (21.4)91.5 (13.1)n.s.
Insulinemia (mg/dL)8.1 (7.2)10.5 (9.2)n.s.
HOMA-IR1.8 (1.5)2.4 (2.1)n.s.
FGIR17.5 (10.3)14.6 (10.3)n.s.
Adiponectin (μg/mL)12.8 (2.1)13.7 (2.2).047
Leptin (ng/mL)10.8 (13.7)7.7 (8.1)n.s.
C-reactive protein (mg/L)3.65 (3.98)6.33 (8.52).048

values by -test, Mann-Whitney test or Chi-square test; n.s.: not significant.
3.2. Adiponectin Correlations to Biochemical and Clinical Parameters in CF Patients

Table 3 shows the correlations observed between adiponectin, biochemical, and FEV parameters in active and sedentary CF patients. Adiponectin correlated negatively with both FEV1% decrease per year as well as with FEV% decrease only in the active group. In addition, adiponectin correlated negatively with lipid biomarkers; in particular, we observed a negative correlation with total cholesterol (chol), LDL, and non-HDL chol in both groups. Finally, serum triglyceride levels correlated negatively with adiponectin levels only in the active group.


CF physical activity group
()
CF sedentary group
()

FEV1% decrease/year.013 (-)
FEV1% decrease (%).025 (-)
Total cholesterol.024 (-).022 (-)
Triglycerides.003 (-)
LDL cholesterol.023 (-).024 (-)
Non-HDL cholesterol.013 (-).043 (-)
C-reactive protein.011 (+)

values by Pearson correlation or by Spearman’s rho correlation.
3.3. Adiponectin Oligomerization State Analysis in Serum by Western Blotting

The distribution of serum adiponectin in sedentary and active CF patients was analysed and compared to the healthy control group by western blot (Figure 1). Three bands corresponding to HMW (≥250 kDa), MMW (180 kDa), and LMW (70 kDa) oligomers were evident in serum from both controls and patients (Figure 1(a)). The densitometric evaluation of adiponectin oligomers in serum showed an increased expression of the HMW, MMW, and LMW oligomers in CF patients compared to controls (Figure 1(b)) (). On the other hand, adiponectin oligomers were only slightly more highly expressed (not statistically significant) in active CF patients compared to healthy controls but significantly lower expression compared to sedentary CF patients.

4. Discussion

Serum adiponectin levels were significantly higher while leptin levels were significantly decreased in CF patients compared to healthy controls. Furthermore, patients with CF that performed 3 years of regular physical activity had adiponectin concentrations significantly lower than those of sedentary patients; in parallel, serum C-reactive protein levels were significantly lower in the active CF group than in the sedentary CF group. Interestingly, in the active CF group, adiponectin levels were negatively correlated with FEV1% decrease per year, FEV1% decrease, and serum CRP. In addition, adiponectin levels were negatively correlated with lipid profiles in the entire cohort of CF patients. Regarding leptin levels, patients with CF that performed 3 years of regular physical activity had increased levels compared to sedentary patients, although data are not significant.

CF is characterized by systemic inflammation associated with progressive airflow obstruction (FEV1), airway neutrophilic inflammation, and recurrent exacerbations; these phenotypical and pathologic features are shared with COPD [10]. In this context, looking at adiponectin and leptin as important modulators of inflammatory processes implicated in airway pathophysiology, we found that serum levels of adiponectin were significantly increased in CF patients compared to healthy controls while leptin levels were significantly decreased in the total cohort of CF patients compared to healthy controls. Moriconi et al. reported increased serum adiponectin in CF patients than in controls, independently of other confounders [26]. In line with these results, significantly increased adiponectin concentrations and a direct correlation to the severity of disease have been observed in patients affected by COPD [11, 2730]. In addition, a relationship between adiponectin concentration and lung function decline has been reported [31]. More recently, an involvement of adiponectin has been described during the pathogenesis of emphysema [16, 28]. Contrasting results are observed for leptin levels in patients with CF [3236].

Previously, we reported that long-term physical exercise had significantly beneficial effects on FEV1% decline, BMI, waist and arm circumferences, and lipid and glucose metabolism in CF patients [6]. In the present study, we examined the effects of physical activity on adiponectin and leptin levels in such patients. Interestingly, we observed that the adiponectin levels significantly decreased with 3 years of regular exercise while leptin levels are increased, although not significant. In particular, in patients with CF, long-term physical exercise produces both an amelioration of the pulmonary phenotype and an improvement of systemic inflammation as demonstrated by the FEV1% decrease, by CRP and adiponectin reduction, and the increase of leptin serum levels. Furthermore, the negative correlation between adiponectin and FEV1% decrease/year and FEV1% decrease observed in the active group of CF patients is consistent with this hypothesis. On the other hand, adiponectin levels are usually elevated in classic chronic inflammatory/immune diseases such as multiple sclerosis, common variable immunodeficiency, and inflammatory bowel disease [9, 3739]. In this context, our data highlight the key role of adiponectin in lung pathologies as a crosstalk between lung and adipose tissue. Our data also underline a correlation between adiponectin and the lipid profile of CF patients. In our cohort of CF patients performing regular exercise for 3 years, physical training induces the mobilization of triglycerides, improving the metabolic profile that correlates with adiponectin levels. Panagopoulou et al. previously demonstrated that adiponectin is higher in CF patients than in controls with lower levels in malnourished young patients and higher in patients with normal nutrition. The authors concluded that this may be attributed to the energy deficit due to the disease [40]. Ziai et al. demonstrated that the association between total adiponectin and glucose and insulin metabolism is different in CF patients compared to controls, although they found similar levels of adiponectin between CF patients and controls [33].

In literature, conflicting data are present on leptin concentrations and its role in CF patients [3236]. To our knowledge, no data about physical activity on leptin levels are reported. In this study, we observed that leptin levels are slightly increased in active CF vs. sedentary patients. These results are in line with previously reported data that observed different concentrations of leptin according to CF disease phenotype and concluded that severe CF patients had significantly decreased leptin compared to controls [35]. This data indicated that leptin may be a further indicator of inflammatory status in patients with CF. However, a limitation of the study is represented by the limited number of CF patients and controls analysed.

5. Conclusion

In conclusion, our results indicate that in CF patients, long-term physical exercise ameliorates the pulmonary phenotype and improves the metabolic profile and systemic inflammation as shown by serum CRP reduction, adiponectin decrease, and leptin increase. Recently, immunometabolic pathomechanisms have been identified as important factors determining and modulating lung function and disease [41]. Therefore, both adipokines appear to be an attractive biomarker for monitoring CF progression. Further studies are needed to define the molecular mechanisms through which adiponectin and leptin modulates such effects.

Data Availability

No sensitive data concerning the patients has been included in the article.

Conflicts of Interest

The authors declare that there is no conflict of interest regarding the publication of this paper.

Authors’ Contributions

Rita Polito, Ersilia Nigro, and Ausilia Elce contributed equally to this work.

Acknowledgments

We acknowledge Ministero della Salute (Rome, Italy) L.548/93 for the regional research funding quote of years 2007-12.

References

  1. P. Aghasafari, U. George, and R. Pidaparti, “A review of inflammatory mechanism in airway diseases,” Inflammation Research, vol. 68, no. 1, pp. 59–74, 2019. View at: Publisher Site | Google Scholar
  2. N. Palaniyar, M. A. Mall, C. Taube, S. Worgall, and H. Grasemann, “New developments in cystic fibrosis airway inflammation,” Mediators of Inflammation, vol. 2015, Article ID 769425, 2 pages, 2015. View at: Publisher Site | Google Scholar
  3. M. Cohen-Cymberknoh, E. Kerem, T. Ferkol, and A. Elizur, “Airway inflammation in cystic fibrosis: molecular mechanisms and clinical implications,” Thorax, vol. 68, no. 12, pp. 1157–1162, 2013. View at: Publisher Site | Google Scholar
  4. R. R. Zhao, A. J. O’Sullivan, and M. A. Fiatarone Singh, “Exercise or physical activity and cognitive function in adults with type 2 diabetes, insulin resistance or impaired glucose tolerance: a systematic review,” European Review of Aging and Physical Activity, vol. 15, no. 1, 2018. View at: Publisher Site | Google Scholar
  5. M. A. Spruit, F. Pitta, E. McAuley, R. L. ZuWallack, and L. Nici, “Pulmonary rehabilitation and physical activity in patients with chronic obstructive pulmonary disease,” American Journal of Respiratory and Critical Care Medicine, vol. 192, no. 8, pp. 924–933, 2015. View at: Publisher Site | Google Scholar
  6. A. Elce, E. Nigro, M. Gelzo et al., “Supervised physical exercise improves clinical, anthropometric and biochemical parameters in adult cystic fibrosis patients: a 2-year evaluation,” The Clinical Respiratory Journal, vol. 12, no. 7, pp. 2228–2234, 2018. View at: Publisher Site | Google Scholar
  7. M. Liu and F. Liu, “Transcriptional and post-translational regulation of adiponectin,” Biochemical Journal, vol. 425, no. 1, pp. 41–52, 2010. View at: Publisher Site | Google Scholar
  8. E. Nigro, O. Scudiero, M. L. Monaco et al., “New insight into adiponectin role in obesity and obesity-related diseases,” BioMed Research International, vol. 2014, Article ID 658913, 14 pages, 2014. View at: Publisher Site | Google Scholar
  9. A. Daniele, A. de Rosa, M. de Cristofaro et al., “Decreased concentration of adiponectin together with a selective reduction of its high molecular weight oligomers is involved in metabolic complications of myotonic dystrophy type 1,” European Journal of Endocrinology, vol. 165, no. 6, pp. 969–975, 2011. View at: Publisher Site | Google Scholar
  10. E. Signoriello, G. Lus, R. Polito et al., “Adiponectin profile at baseline is correlated to progression and severity of multiple sclerosis,” European Journal of Neurology, vol. 26, no. 2, pp. 348–355, 2019. View at: Publisher Site | Google Scholar
  11. A. Daniele, A. de Rosa, E. Nigro et al., “Adiponectin oligomerization state and adiponectin receptors airway expression in chronic obstructive pulmonary disease,” The International Journal of Biochemistry & Cell Biology, vol. 44, no. 3, pp. 563–569, 2012. View at: Publisher Site | Google Scholar
  12. E. Nigro, O. Scudiero, D. Sarnataro et al., “Adiponectin affects lung epithelial A549 cell viability counteracting TNFα and IL-1β toxicity through AdipoR1,” The International Journal of Biochemistry & Cell Biology, vol. 45, no. 6, pp. 1145–1153, 2013. View at: Publisher Site | Google Scholar
  13. R. Summer, F. F. Little, N. Ouchi et al., “Alveolar macrophage activation and an emphysema-like phenotype in adiponectin-deficient mice,” American Journal of Physiology. Lung Cellular and Molecular Physiology, vol. 294, no. 6, pp. L1035–L1042, 2008. View at: Publisher Site | Google Scholar
  14. R. Summer, C. A. Fiack, Y. Ikeda et al., “Adiponectin deficiency: a model of pulmonary hypertension associated with pulmonary vascular disease,” American Journal of Physiology. Lung Cellular and Molecular Physiology, vol. 297, no. 3, pp. L432–L438, 2009. View at: Publisher Site | Google Scholar
  15. M. Illiano, E. Nigro, L. Sapio et al., “Adiponectin down-regulates CREB and inhibits proliferation of A549 lung cancer cells,” Pulmonary Pharmacology & Therapeutics, vol. 45, pp. 114–120, 2017. View at: Publisher Site | Google Scholar
  16. P. Boura, S. Loukides, D. Grapsa, A. Achimastos, and K. Syrigos, “The diverse roles of adiponectin in non-small-cell lung cancer: current data and future perspectives,” Future Oncology, vol. 11, no. 15, pp. 2193–2203, 2015. View at: Publisher Site | Google Scholar
  17. N. Yu, Y. Ruan, X. Gao, and J. Sun, “Systematic review and meta-analysis of randomized, controlled trials on the effect of exercise on serum leptin and adiponectin in overweight and obese individuals,” Hormone and Metabolic Research, vol. 49, no. 03, pp. 164–173, 2017. View at: Publisher Site | Google Scholar
  18. P. M. Farrell, B. J. Rosenstein, T. B. White et al., “Guidelines for diagnosis of cystic fibrosis in newborns through older adults: Cystic Fibrosis Foundation consensus report,” The Journal of Pediatrics, vol. 153, no. 2, pp. S4–14, 2008. View at: Publisher Site | Google Scholar
  19. L. G. VA, J. R. Yankaskas, L. M. Quittell, B. C. Marshall, P. J. Mogayzel Jr., and Cystic Fibrosis Foundation, “Diagnostic sweat testing: the Cystic Fibrosis Foundation guidelines,” The Journal of Pediatrics, vol. 151, no. 1, pp. 85–89, 2007. View at: Publisher Site | Google Scholar
  20. R. Tomaiuolo, F. Sangiuolo, C. Bombieri et al., “Epidemiology and a novel procedure for large scale analysis of CFTR rearrangements in classic and atypical CF patients: a multicentric Italian study,” Journal of Cystic Fibrosis, vol. 7, no. 5, pp. 347–351, 2008. View at: Publisher Site | Google Scholar
  21. P. H. Quanjer, S. Stanojevic, T. J. Cole et al., “Multi-ethnic reference values for spirometry for the 3–95-yr age range: the global lung function 2012 equations,” The European Respiratory Journal, vol. 40, no. 6, pp. 1324–1343, 2012. View at: Publisher Site | Google Scholar
  22. D. Debray, D. Kelly, R. Houwen, B. Strandvik, and C. Colombo, “Best practice guidance for the diagnosis and management of cystic fibrosis-associated liver disease,” Journal of Cystic Fibrosis, vol. 10, pp. S29–S36, 2011. View at: Publisher Site | Google Scholar
  23. J. F. Ascaso, S. Pardo, J. T. Real, R. I. Lorente, A. Priego, and R. Carmena, “Diagnosing insulin resistance by simple quantitative methods in subjects with normal glucose metabolism,” Diabetes Care, vol. 26, no. 12, pp. 3320–3325, 2003. View at: Publisher Site | Google Scholar
  24. http://www.euro.who.int/en/health-topics/disease-prevention/nutrition/a-healthy-lifestyle/body-mass-index-bmi.
  25. E. Nigro, P. Piombino, O. Scudiero et al., “Evaluation of salivary adiponectin profile in obese patients,” Peptides, vol. 63, pp. 150–155, 2015. View at: Publisher Site | Google Scholar
  26. N. Moriconi, M. Kraenzlin, B. Müller et al., “Body composition and adiponectin serum concentrations in adult patients with cystic fibrosis,” The Journal of Clinical Endocrinology and Metabolism, vol. 91, no. 4, pp. 1586–1590, 2006. View at: Publisher Site | Google Scholar
  27. S. Jaswal, V. Saini, J. Kaur, S. Gupta, H. Kaur, and K. Garg, “Association of adiponectin with lung function impairment and disease severity in chronic obstructive pulmonary disease,” International Journal of Applied & Basic Medical Research, vol. 8, no. 1, pp. 14–18, 2018. View at: Publisher Site | Google Scholar
  28. H. Kanazawa and T. Yoshikawa, “Association of plasma adiponectin levels with cellular hydration state measured using bioelectrical impedance analysis in patients with COPD,” International Journal of Chronic Obstructive Pulmonary Disease, vol. 7, pp. 515–521, 2012. View at: Publisher Site | Google Scholar
  29. J. G. Shaw, A. Vaughan, A. G. Dent et al., “Biomarkers of progression of chronic obstructive pulmonary disease (COPD),” Journal of Thoracic Disease, vol. 6, no. 11, pp. 1532–1547, 2014. View at: Publisher Site | Google Scholar
  30. B. J. Carolan, Y. I. Kim, A. A. Williams et al., “The association of adiponectin with computed tomography phenotypes in chronic obstructive pulmonary disease,” American Journal of Respiratory and Critical Care Medicine, vol. 188, no. 5, pp. 561–566, 2013. View at: Publisher Site | Google Scholar
  31. K. Sato, Y. Shibata, S. Abe et al., “Association between plasma adiponectin levels and decline in forced expiratory volume in 1 s in a general Japanese population: the Takahata study,” International Journal of Medical Sciences, vol. 11, no. 8, pp. 758–764, 2014. View at: Publisher Site | Google Scholar
  32. M. Monajemzadeh, M. T. H. Ashtiani, E. Sadrian et al., “Variation in plasma leptin levels in young Iranian children with cystic fibrosis,” Archives of Medical Science, vol. 5, no. 5, pp. 883–887, 2013. View at: Publisher Site | Google Scholar
  33. S. Ziai, L. Belson, A. Malet et al., “The association between leptin and insulin levels in adults with cystic fibrosis,” Diabetes & Metabolism, vol. 38, no. 1, pp. 34–39, 2012. View at: Publisher Site | Google Scholar
  34. R. I. Cohen, D. Tsang, S. Koenig, D. Wilson, T. McCloskey, and S. Chandra, “Plasma ghrelin and leptin in adult cystic fibrosis patients,” Journal of Cystic Fibrosis, vol. 7, no. 5, pp. 398–402, 2008. View at: Publisher Site | Google Scholar
  35. M. C. S. Boguszewski, T. O. Kamoi, R. Bento Radominski et al., “Insulin-like growth factor-1, leptin, body composition, and clinical status interactions in children with cystic fibrosis,” Hormone Research, vol. 67, no. 5, pp. 250–256, 2007. View at: Publisher Site | Google Scholar
  36. S. Schmitt-Grohé, V. Hippe, M. Igel et al., “Serum leptin and cytokines in whole blood in relation to clinical and nutritional status in cystic fibrosis,” Journal of Pediatric Gastroenterology and Nutrition, vol. 43, no. 2, pp. 228–233, 2006. View at: Publisher Site | Google Scholar
  37. A. Pecoraro, E. Nigro, R. Polito et al., “Total and high molecular weight adiponectin expression is decreased in patients with common variable immunodeficiency: correlation with Ig replacement therapy,” Frontiers in Immunology, vol. 8, p. 895, 2017. View at: Publisher Site | Google Scholar
  38. N. Morshedzadeh, M. Rahimlou, H. Asadzadeh Aghdaei, S. Shahrokh, M. Reza Zali, and P. Mirmiran, “Association between adipokines levels with inflammatory bowel disease (IBD): systematic reviews,” Digestive Diseases and Sciences, vol. 62, no. 12, pp. 3280–3286, 2017. View at: Publisher Site | Google Scholar
  39. Y. Takeda, K. Nakanishi, I. Tachibana, and A. Kumanogoh, “Adiponectin: a novel link between adipocytes and COPD,” Vitamins and Hormones, vol. 90, pp. 419–435, 2012. View at: Publisher Site | Google Scholar
  40. P. Panagopoulou, M. Fotoulaki, A. Manolitsas, E. Pavlitou-Tsiontsi, I. Tsitouridis, and S. Nousia-Arvanitakis, “Adiponectin and body composition in cystic fibrosis,” Journal of Cystic Fibrosis, vol. 7, no. 3, pp. 244–251, 2008. View at: Publisher Site | Google Scholar
  41. S. Bruzzaniti, M. Bocchino, M. Santopaolo et al., “An immunometabolic pathomechanism for chronic obstructive pulmonary disease,” Proceedings of the National Academy of Sciences, vol. 116, no. 31, pp. 15625–15634, 2019. View at: Publisher Site | Google Scholar

Copyright © 2019 Rita Polito et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


More related articles

655 Views | 269 Downloads | 4 Citations
 PDF  Download Citation  Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.